Biotech Healthcare Hong Kong Investment IPO Medicine Pharmaceutical stock market Technology
Exploring the potential in the primary market and the execution in the secondary market, the essence of the valuation difference lies in the cognitive gap, leading to a dilemma in the IPO decisions of companies. As HKEX in November 2025 hosts a continuous queue of IPOs for innovative pharmaceutical companies, it sets a new record with over 80 biopharmaceutical companies in various stages of application processing, submission, and preparation. Concurrently, 23 healthcare companies have successfully landed on HKEX, indicating a robust valuation system reconstructing as a core driving force for companies flocking to Hong Kong. With the market sentiment of…
News Timeline:
Track the development of this news story across the Internet.